Edgar Turner Overton, CROI 2022: Long-acting Cabotegravir + Rilpivirine for the maintenance of HIV – ATLAS-2M Week 152 Results
The ATLAS-2M, week 152 efficacy and safety findings (NCT03299049) investigating long-acting cabotegravir + rilpivirine for the maintenance of HIV-1 virologic suppression, are discussed in this video interview with Dr Edgar Turner Overton (University of Alabama at Birmingham, Birmingham, AL, USA). He discusses the rationale behind increasing the dosing frequency of long acting cabotegravir + rilpivirine from every 4 weeks to every 8 weeks, the study findings and takes a look into what impact these findings might have on people living with HIV.
The abstract entitled: ‘Long-Acting Cabotegravir + Rilpivirine Every 2 Months: ATLAS-2M Week 152 Results’ (Abstract #479) was presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2022 (Virtual), 12-16 February 2022.
- What is the rationale for increasing the dosing frequency of long acting cabotegravir and rilpivirine from every 4 weeks to every 8 weeks in the treatment of HIV? (0:29)
- What were the aims, design and inclusion criteria of the ATLAS-2M study? (1:03)
- What were the efficacy and safety findings at 152 week, and how do these compare to the 96 week findings? (2:15)
- What will be the impact of these findings on people living with HIV? (4:22)
Disclosures: Edgar Turner Overton has served as a consultant for ViiV and Merck.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of CROI 2022.
Share this Video
Related Videos In HIV
Sunil Solomon, CROI 2023: Unknowns and hurdles surrounding long-acting injectable PrEP for the prevention of HIV
touchINFECTIOUSDISEASES were delighted to speak with Dr Sunil Solomon (The Johns Hopkins University School of Medicine, Baltimore, MD, USA) about the hurdles surrounding the use of long-acting injectable pre-exposure prophylaxis (PrEP) for the prevention of HIV in at-risk populations. Dr Solomon discussed the main barriers to conducting HIV research in at-risk populations, such as people […]
Sunil Solomon, CROI 2023: Current knowledge surrounding long-acting injectable PrEP for the prevention of HIV
It was a pleasure to talk with Dr Sunil Solomon (The Johns Hopkins University School of Medicine, Baltimore, MD, USA) about the evidence from clinical trials for the use of long-acting injectables in the prevention of HIV and how long-acting injectable cabotegravir compares to oral pre-exposure prophylaxis (PrEP). Dr Solomon also discussed who is most […]
Nyaradzo Mgodi, CROI 2023: Long-acting injectable PrEP and cabotegravir roll-out for prevention of HIV- Factors affecting clinical practice and policy making
Long-acting injectable pre-exposure prophylaxis (PrEP) with cabotegravir has recently been approved as a new HIV prevention method. The preventative treatment involves receiving an injection of cabotegravir every two months to prevent HIV infection, rather than taking daily oral medication. The roll-out of this new prevention method is affected by several factors in both clinical practice […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!